When ChondroFiller is the right fit for your hip

Not every hip cartilage problem is suited to ChondroFiller — and understanding that distinction early saves time and sets realistic expectations.

The treatment targets focal, isolated Grade III/IV articular cartilage defects on the femoral head or acetabulum, ideally where the surrounding cartilage border remains healthy. The most common causes are femoroacetabular impingement (FAI), a direct hip injury, or early focal degeneration affecting a discrete area rather than the whole joint surface. The mechanism is acellular matrix-induced chondrogenesis: the injectable collagen scaffold recruits the patient's own progenitor cells to support tissue remodelling within the defect.

Defect size is clinically meaningful. The strongest published hip-specific data — a prospective cohort study by Mazek (2021, PMC8460160) following 26 adults over three to five years — focused on acetabular lesions greater than 2 cm², with 17 of 21 evaluable patients achieving good or excellent results at that threshold.

ChondroFiller is not suitable for diffuse, advanced hip wear. Patients with established osteoarthritis spreading across the joint — equivalent to Tönnis grade 2–3 — showed poor outcomes in the same cohort and are better directed towards other pathways.

Before contacting any provider, a recent hip MRI is essential: defect mapping from imaging determines both whether the injection pathway is appropriate and how many scaffold units would be required.

Five things every ChondroFiller hip provider should offer

Choosing the right provider matters as much as choosing the right treatment. The five criteria below are a practical checklist for anyone comparing ChondroFiller hip injection clinics across the UK.

1. Pre-treatment MRI review The number of scaffold units required and where they are placed within the hip joint are both determined from imaging — not from a telephone assessment. Red flag: a clinic that agrees a treatment plan before reviewing your hip MRI.

2. Real-time image-guided delivery The hip is a deep, constrained joint; accurate outpatient placement of ChondroFiller requires live ultrasound or fluoroscopic guidance throughout the procedure. Not every general injection clinic is equipped for this. Red flag: no mention of imaging guidance, or only post-injection confirmation.

3. Transparent, all-inclusive pricing A well-structured package covers the consultation, real-time imaging guidance, the ChondroFiller implant itself, intravenous antibiotic cover, and a six-week follow-up appointment. UK guide costs run from approximately £3,000 (one box, most focal hip defects) to £8,000 where multiple units are needed. Red flag: a quoted figure that excludes the implant cost or follow-up, making the headline price misleading.

4. Clear explanation of which pathway suits your defect For larger or more complex hip cartilage lesions, the Liquid Cartilage™ protocol — where the scaffold is placed arthroscopically under anaesthesia — may be more appropriate than an outpatient injection. A trustworthy provider explains the distinction and directs patients accordingly. Red flag: only one pathway offered regardless of defect size or complexity.

5. Verifiable outcome data from the provider's own cases A clinic that has treated a meaningful cohort will be able to show its own results alongside published evidence. Quoting manufacturer figures alone suggests limited real-world experience. Red flag: outcomes discussed only in general terms, with no reference to the clinic's own patient cohort.

What the hip injection appointment actually involves

On the day itself, the appointment is straightforward and takes around 30 minutes in a clinic room — no theatre admission, no general anaesthetic, and no surgical incision.

With the MRI review and clinical assessment completed beforehand, the treating clinician already knows the defect location and how many scaffold units are needed. The injection is carried out under local anaesthesia. Once the collagen scaffold is placed into the hip joint space, it sets within minutes, filling the defect and giving the patient's own cells a physical framework to migrate into over the weeks that follow.

Most patients are able to walk out of the clinic unaided the same day, though a short rest period immediately after the injection is standard. Activity is typically restricted for a defined period — the treating clinician confirms this at the consultation, as it varies with defect size and location. Driving on the day of treatment is not usually advised.

For most single focal hip defects, one session is sufficient. A follow-up appointment — included as part of the standard package — takes place at around six weeks to monitor recovery and assess the joint's response. Patients who travel from outside the area can usually arrange both the pre-treatment consultation and any follow-up remotely where the clinical situation allows.

Cost, self-funding, and finance across the UK

ChondroFiller is not available through the NHS and is not routinely covered by Bupa, AXA, or other major UK private medical insurers — so the cost falls to the patient in full. That is worth stating plainly before comparing providers.

What guide prices look like across the UK

UK-wide, self-funded costs run from approximately £3,000 for a single-box course to £8,000 where three boxes are needed. Most focal hip cartilage defects require one box, placing most patients toward the lower end of that range.

Pricing structures vary between providers. When comparing quotes, the central question is what each figure actually covers: whether all clinical components are bundled into one figure or charged as separate line items. A lower headline price that excludes some elements may ultimately cost more than a genuinely all-inclusive package — the checklist in the previous section is a useful reference when asking.

Lincolnshire access and pricing

At Lincolnshire Hip (part of MSK Doctors), the guide price is £2,995 per injection, inclusive of the full appointment package. That sits below the upper end of the UK-wide range and, for patients in the region, avoids the travel and accommodation costs that a London visit would typically add.

Finance is available through Kandoo, MSK Doctors' funding partner — a practical option for patients managing an upfront self-funded payment rather than waiting to save the full amount.

Before agreeing a cost

No firm price should be confirmed before a recent hip MRI has been reviewed, because defect size and placement determine how many boxes are required. A quote given without imaging is at best provisional. Patients can self-refer without a GP referral, but bringing current MRI to the first appointment allows defect mapping to take place before a treatment plan — or a final cost — is agreed.

ChondroFiller for the hip in Lincolnshire

Named UK ChondroFiller providers are concentrated in London — principally the London Cartilage Clinic on Harley Street — and Scotland, where Mr Turab Syed operates from BMI Kings Park Hospital in Stirling and the Lanarkshire Clinic in Hamilton. No other Lincolnshire clinic currently offers ChondroFiller for the hip, which represents a meaningful access gap for patients across the East Midlands and surrounding counties.

The Lincolnshire Hip Clinic, a trading name of MSK Doctors, treats focal hip cartilage defects using ultrasound-guided ChondroFiller injection at clinical sites in Grantham and Sleaford (head office: London Road, Silk Willoughby, NG34 8NY). The clinic is led by Professor Paul Lee (FRCS Tr&Orth, PhD), Honorary Professor at the University of Lincoln and Royal College of Surgeons of Edinburgh Ambassador. Professor Lee is documented as the first clinician in the UK to have delivered ChondroFiller as an outpatient injection — experience that predates the treatment's wider adoption and reflects sustained familiarity with how the scaffold behaves specifically in the hip joint.

Lincolnshire Hip operates as a hip-only clinical pathway. Assessment, MRI review, treatment planning, and six-week follow-up are all managed within a hip-specific rather than a general MSK framework. For a procedure that depends on precise joint anatomy, defect geometry, and real-time imaging guidance, that clinical focus is directly relevant rather than incidental.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

Realistic outcomes and what happens after the injection

The published hip-specific outcome data from Mazek (2021) records an improvement of approximately +33 Harris Hip Score points and a reduction of around 6 points on the visual analogue pain scale — meaningful functional and symptomatic gains in a patient group with established acetabular cartilage damage. Those figures add clinical texture to the outcome picture, but they come from a modest prospective cohort rather than a large randomised controlled trial and should be read in that spirit.

Across the broader ChondroFiller evidence base — encompassing knee, hip, and small-joint applications across more than 19,000 treated cases internationally — 70–85% of patients achieve meaningful symptom relief at three to five years, with no serious complications reported in published series. The hip-specific figures sit within that wider range, though no published outcome data specific to any single UK regional provider yet exists; patients choosing a non-London clinic are drawing on the same international evidence pool that all providers cite.

Results depend materially on defect size, the condition of surrounding cartilage, and accurate patient selection at the outset. ChondroFiller supports the body's own repair processes in focal Grade III/IV defects — it is not indicated for diffuse joint-wide hip degeneration, where published data show poor outcomes.

The Lincolnshire Hip package includes a six-week follow-up appointment. If that review identifies an incomplete response or ongoing deterioration, the clinical conversation typically turns to alternative hip preservation strategies — including arthroscopic approaches or, where the joint has progressed beyond preservation, hip replacement planning — rather than simply repeating the same injection.